CG Oncology, Inc.
CGON · Biotech · Nasdaq · As of 10 Sep 2026
- FundamentalsNot enough data yet
- ValueNot enough data yet
- News flowBalanced
- MomentumStrong
- SafetyStrong
Overall confidence 38/100 — few inputs available yet
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.
Discovery Gap: Medium (13/100) · Gap confidence 55/100Some evidence isn't yet fully priced in.
This month at a glance
AIR Score™ change: 0AIR Score™ held steady this month.
Cycle window9 Sep 2026 → 10 Sep 2026
MoversNothing moved meaningfully this month.
Evidence timeline
- [8-K 2.02] CG Oncology, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGARAug 6, 2026 · 8-K
- [8-K 8.01] CG Oncology, Inc. — Other EventsSEC · SEC EDGARAug 6, 2026 · 8-K
- [8-K 5.02] CG Oncology, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARMay 20, 2026 · 8-K
- [8-K 2.02] CG Oncology, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGARMay 8, 2026 · 8-K
- [8-K 5.02] CG Oncology, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARApr 13, 2026 · 8-K
- [8-K 2.02] CG Oncology, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGARFeb 27, 2026 · 8-K
- [8-K 8.01] CG Oncology, Inc. — Other EventsSEC · SEC EDGARJan 13, 2026 · 8-K
- [8-K 8.01] CG Oncology, Inc. — Other EventsSEC · SEC EDGARJan 9, 2026 · 8-K
- [8-K 5.02] CG Oncology, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARNov 22, 2025 · 8-K
- [8-K 2.02] CG Oncology, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGARNov 14, 2025 · 8-K
- [8-K 5.02] CG Oncology, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARNov 10, 2025 · 8-K
- [8-K 8.01] CG Oncology, Inc. — Other EventsSEC · SEC EDGARSep 5, 2025 · 8-K
Ask AIR
What would change our view
A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.